Loading...
Loading...
ARDS| Name | Value |
|---|---|
| Revenues | 19.6M |
| Cost of Revenue | 0.0M |
| Gross Profit | 19.6M |
| Operating Expense | 6.0M |
| Operating I/L | 13.7M |
| Other Income/Expense | -1.5M |
| Interest Income | 0.0M |
| Pretax | 12.1M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | 12.1M |
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company specializing in targeted immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. Their lead product candidate, AR-301, is in Phase III pivotal trials for treating lung infections caused by S. aureus alphatoxin. The company is also developing a range of other fully human monoclonal antibodies targeting various infections, including those caused by methicillin-resistant Staphylococcus aureus, gram-negative bacteria P. aeruginosa, Acinetobacter baumannii, and respiratory syncytial virus. Additionally, they have anti-infective therapies in clinical trials for managing chronic lung infections in cystic fibrosis patients and treating non-hospitalized COVID-19 patients.
